UPDATE: Roth Capital Starts Bio-Path Holdings (BPTH) at Buy

March 11, 2021 4:44 AM EST
Get Alerts BPTH Hot Sheet
Price: $5.99 +1.35%

Rating Summary:
    3 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 10 | New: 17
Trade Now! 
Join SI Premium – FREE
(Updated - March 11, 2021 5:03 AM EST)

Roth Capital analyst Philip Shen initiates coverage on Bio-Path Holdings (NASDAQ: BPTH) with a Buy rating and a price target of $13.00.

The analyst comments "Bio-Path Holdings is a clinical-stage oncology company engaged in discovering, developing, and ultimately commercializing novel singe-stranded DNA antisense drugs for hematological and solid tumors. BPTH’s pipeline consists of two clinical stage drugs and two preclinical drugs, with Phase 1 trials expected to begin for the latter two later in 2021, and all of which were created using the company’s proprietary DNAbilize drug production technology. We look forward to value creating clinical results from its four programs from 3Q21 to 1Q23."

For an analyst ratings summary and ratings history on Bio-Path Holdings click here. For more ratings news on Bio-Path Holdings click here.

Shares of Bio-Path Holdings closed at $6.29 yesterday.


You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Roth Capital